ID
24391
Description
GSK study: Ropinirole in RLS patients 101468/243 - RLS Forms Baseline, Day2 Week 1-52, Early withdrawal and Follow-up Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome
Keywords
Versions (1)
- 7/30/17 7/30/17 -
Copyright Holder
glaxoSmithKline
Uploaded on
July 30, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK study: Ropinirole in RLS patients 101468/243 - RLS Forms Baseline, Day2 Week 1-52, Early withdrawal and Follow-up
GSK study: Ropinirole in RLS patients 101468/243 - RLS Forms Baseline, Day2 Week 1-52, Early withdrawal and Follow-up
Description
RLS Rating scale - Day 2
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 1
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 2
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 3
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 4
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 5
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 6
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 7
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 8
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 12
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 24
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 36
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 48
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Week 52
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Early Withdrawal
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Description
RLS Rating scale - Follow-up
Alias
- UMLS CUI-1
- C0681889
- UMLS CUI-2
- C0035258
Similar models
GSK study: Ropinirole in RLS patients 101468/243 - RLS Forms Baseline, Day2 Week 1-52, Early withdrawal and Follow-up
C0035258 (UMLS CUI-2)
C0282121 (UMLS CUI-3)
C0035258 (UMLS CUI [1,2])
C0282121 (UMLS CUI [1,3])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])